Deals & Capital Markets
Royalty Pharma Bets $500M on Teva's Vitiligo Antibody, Targeting Market With Only One Approved Drug
3d ago
You're signed outSign in or to get full access.
TP
TEVA PHARMACEUTICAL INDUSTRIES (TEVA)·Earnings Reports
Q3 2025
View earnings summary and analysis
Q2 2025
View earnings summary and analysis
Q1 2025
View earnings summary and analysis
Q4 2024
View earnings summary and analysis
Research analysts covering TEVA PHARMACEUTICAL INDUSTRIES.